A Phase 2/3 interventional study of treprostinil sodium and Placebo in Liver Transplant, sponsored by United Therapeutics. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-19.
Sponsored by United Therapeutics · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Reperfusion Injury with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Reperfusion Injury · United States.
Among the 44 studies in Reperfusion Injury with a site in United States, this one is the 36th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2008, is one of 4 in phase 2/3, and was the 24th registered.
260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.
Browse Reperfusion Injury studies →5 of the 44 studies in Reperfusion Injury with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Boston Children's Hospital · Sites in United States
Rhode Island Hospital · Sites in United States
Ages 18–75
Gary Van Guilder · Sites in United States
Ages 18–65 · Healthy volunteers
Mitovation, Inc · Sites in United States
Ages 48 hrs–1 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Reperfusion Injury studies recruiting now, 16 (57%) set no upper age limit and 7 (25%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 18 · Phase 3 7 · Phase 4 1
First in 1997; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 30 across the 39 interventional studies, 20 across the 5 observational. Of the 32 that completed or were terminated, 13 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
United Therapeutics has 1 study filed under Reperfusion Injury — fewer than ten, so there is no comparison to draw.
3 of the studies in Reperfusion Injury with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03663543University of PennsylvaniaIntravenous Estrogen in Kidney Transplant Study | 2027-01-31 |
| NCT05574296Boston Children's HospitalHydrogen's Feasibility and Safety as a Therapy in ECPR | 2027-03-31 |
| NCT07385651Vanderbilt University Medical CenterDeceased Donor Kidney Storage at 10 Celsius Versus Conventional Storage | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 44 studies in Reperfusion Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients undergoing orthotopic liver transplant will experience some degree of clinical and/or biochemical hepatic dysfunction. This early injury is known as primary graft dysfunction and varies from minor abnormalities to primary nonfunction. Prostaglandin-class drugs, including prostacyclin and its analogs, could represent an important advance toward the goal of reducing transplant related morbidity, mortality and associated costs by providing these benefits.
In vitro and in vivo research has consistently demonstrated an array of potential beneficial effects of prostanoids under both immune and non-immune circumstances relevant to liver allografts. (1-3) Recent reviews summarize the pharmacologic rationale and nonclinical and clinical experience supporting for the use of prostanoids, including prostacyclin and its analogs, in reducing early morbidity and mortality associated with liver transplantation. Prostaglandin-class drugs, including prostacyclin and its analogs, could represent an important advance toward the goal of reducing transplant related morbidity, mortality and associated costs by providing these benefits. Additionally, the reduction in serum creatinine and reduced need for post-operative dialysis observed in some studies has implications in protecting the kidneys from the nephrotoxic affects of the immunosuppressant agents, especially during the early post-operative period.
As a chemically stable analog of prostacyclin (PGI2), peri-operative intravenous administration of Remodulin is hypothesized to ameliorate or prevent reperfusion damage and thereby decrease hospitalization time and improve the clinical outcome of liver transplantation, compared to placebo control. Remodulin, as a prostanoid, is expected to facilitate restoration of the blood supply to the revascularized graft, and to provide the well-characterized protective effects of this class of compounds in liver transplant patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Remodulin initiated as a continuous IV infusion at a dose of 2.5 ng/kg/min after subjects have been assessed as hemodynamically stable in the ICU. Dose may be escalated in 1.25- to 2.5-ng/kg/min increments, up to 7.5 ng/kg/min, with a target dose of 5 ng/kg/min, based on tolerability. The dose will be maintained at the maximum tolerated dose, not to exceed 7.5 ng/kg/min for 5 days after the transplantation surgery.
Drug: treprostinil sodium
Matching placebo
Drug: Placebo
A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials. The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative
Also known as: Remodulin, UT 15
Duration of the initial hospitalization (days) following transplantation
Time frame: up to 180 days
Area under the curve (AUC) of serum aspartate transaminase (AST) levels.
The difference in serum AST as measured by AUC during the first seven days post-transplant will be compared between placebo and Remodulin treatment groups. AST is a serum transaminase marker of hepatic injury, and the AUC of AST levels represents the total magnitude of injury the liver experiences against time.
Time frame: 7 days
Serum AST and alanine transaminase (ALT ) levels after transplant (Peak and Area Under the Curve [AUC])
Time frame: 7 days
Primary allograft nonfunction defined as patient death or retransplant within 30 days due to liver failure
Time frame: 30 days
Graft survival
Time frame: 30 days, 90 days and 180 days
Subject survival at
Time frame: Day 30, 90, and 180
Post-transplant renal function
Time frame: 30 days
Duration of time spent in the intensive care unit (ICU; days) during the initial hospitalization.
Time frame: up to 180 days
Intra-operative blood product usage
Time frame: 1 day
Death from any cause
Time frame: 180 days
Total costs for initial transplant hospitalization
Time frame: up to 180 days
The record gives a start of Jun 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil